KIF3C and gastric adenocarcinoma: Notably, in patients with stomach adenocarcinoma (STAD) who had higher KIF3C expression levels, there was increased sensitivity to specific drugs, including Axitinib, Bexarotene, Dasatinib, Doxorubicin, Elesclomol, Embelin, Etoposide, Imatinib, Nilotinib, Pazopanib, Shikonin, and Vorinostat.